GlassScriptPhysician profile
Jorge A Loredo
NPI 1073567640
$15,182.78
in general payments reported to CMS, 2019-2025
43 companies · $1,452 in 2025
The $1,452 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,855 · 2020: $2,255 · 2021: $2,803 · 2022: $2,798 · 2023: $2,296 · 2024: $1,723 · 2025: $1,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,471.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,553.47 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,310.22 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,231.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,115.12 | 2019-2025 | Jardiance |
| Abbvie INC. | $1,014.86 | 2020-2025 | |
| Glaxosmithkline, LLC. | $929.13 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $687.03 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $594.36 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $585.23 | 2019-2023 | Seglentis |
| Sanofi-Aventis U.S. LLC | $558.84 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $449.86 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $437.73 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Amneal Pharmaceuticals LLC | $339.97 | 2019-2025 | Unithroid |
| Scilex Pharmaceuticals INC. | $323.27 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $308.96 | 2019-2025 | Xifaxan |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $303.58 | 2019-2020 | |
| Horizon Therapeutics Plc | $286.02 | 2019-2023 | Krystexxa |
| Amarin Pharma, INC. | $271.05 | 2019-2023 | |
| Amgen INC. | $251.77 | 2023-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $192.84 | 2021-2025 | |
| Corcept Therapeutics | $157.80 | 2022-2025 | Korlym |
| Optinose US, INC. | $139.74 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $137.54 | 2024-2025 | Voquezna |
| Abbott Laboratories | $129.96 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $125.21 | 2022 | |
| Ironwood Pharmaceuticals, INC | $95.50 | 2021-2024 | Linzess |
| Biohaven Pharmaceuticals, INC. | $92.03 | 2021 | |
| Idorsia Pharmaceuticals US INC | $90.89 | 2022-2024 | Quviviq |
| Exact Sciences Corporation | $89.21 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $67.08 | 2024-2025 | Eliquis |
| Currax Pharmaceuticals LLC | $54.82 | 2020-2021 | |
| Astellas Pharma US INC | $46.75 | 2025 | Veozah |
| Evoke Pharma, INC. | $41.87 | 2023-2025 | Gimoti |
| Teva Pharmaceuticals USA, INC. | $37.82 | 2021 | |
| Boston Scientific Corporation | $36.21 | 2023 | Watchman Flx |
| Alexion Pharmaceuticals, INC. | $26.06 | 2021 | |
| Ibsa Pharma INC. | $20.00 | 2023 | Tirosint, Licart |
| Medicure Pharma INC. | $19.24 | 2021 | |
| Eisai INC. | $17.41 | 2020 | |
| Adamas Pharmaceuticals, INC. | $13.32 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Loredo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.